What should we expect from multiple sclerosis therapy? Results of an integrated analysis of delayed-release dimethyl fumarate pivotal trials.

Lanzillo, R

What should we expect from multiple sclerosis therapy? Results of an integrated analysis of delayed-release dimethyl fumarate pivotal trials. [electronic resource] - European journal of neurology 05 2017 - 661-662 p. digital

Publication Type: Editorial; Comment

1468-1331

10.1111/ene.13283 doi


Dimethyl Fumarate
Glatiramer Acetate
Humans
Immunosuppressive Agents
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting